These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Human trials: cell and organ transplantation/other therapeutic approaches--summary and discussion. Barker CF Birth Defects Orig Artic Ser; 1980; 16(1):509-15. PubMed ID: 7448361 [No Abstract] [Full Text] [Related]
4. [Enzyme replacement: recognition and transport of lysosomal enzymes]. González Noriega A Bol Estud Med Biol; 1983; 32(7-8 Suppl 1):209-17. PubMed ID: 6543638 [No Abstract] [Full Text] [Related]
5. [Enzyme defects as molecular diseases]. Aebi H Verh Dtsch Ges Inn Med; 1972; 78():304-13. PubMed ID: 4665667 [No Abstract] [Full Text] [Related]
6. New trends in the treatment of inborn errors of metabolism: an overview. Frézal J; Munnich A; Ogier H; Weil D; Saudubray JM Prog Clin Biol Res; 1982; 103 Pt B():563-71. PubMed ID: 7163247 [No Abstract] [Full Text] [Related]
7. Renal replacement therapy in the treatment of confirmed or suspected inborn errors of metabolism. McBryde KD; Kershaw DB; Bunchman TE; Maxvold NJ; Mottes TA; Kudelka TL; Brophy PD J Pediatr; 2006 Jun; 148(6):770-8. PubMed ID: 16769384 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a clinical pathway for the emergency treatment of patients with inborn errors of metabolism. Zand DJ; Brown KM; Lichter-Konecki U; Campbell JK; Salehi V; Chamberlain JM Pediatrics; 2008 Dec; 122(6):1191-5. PubMed ID: 19047233 [TBL] [Abstract][Full Text] [Related]
9. Letter: Enzyme-carrier potential of liposomes in enzyme replacement therapy. Gregoriadis G N Engl J Med; 1975 Jan; 292(4):215. PubMed ID: 1109221 [No Abstract] [Full Text] [Related]
10. [Future possibilities for the treatment of hereditary metabolic diseases]. Watts RW Monatsschr Kinderheilkd; 1983 Jun; 131(6):305-10. PubMed ID: 6350850 [No Abstract] [Full Text] [Related]
11. Human trials: direct enzyme replacement--summary and discussion. Nadler HL Birth Defects Orig Artic Ser; 1980; 16(1):425-6. PubMed ID: 7004521 [No Abstract] [Full Text] [Related]
12. National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model. Kesselman I; Elstein D; Israeli A; Chertkoff R; Zimran A Blood Cells Mol Dis; 2006; 37(1):46-9. PubMed ID: 16824774 [TBL] [Abstract][Full Text] [Related]
13. [The cost of rehabilitating patients with hearing disorders]. Jauhiainen T Duodecim; 2004; 120(14):1786-7; author reply 1787. PubMed ID: 15497314 [No Abstract] [Full Text] [Related]
14. [Hereditary enzymopathies: problems and prospects]. Vidershoĭn GIa Vopr Med Khim; 1982; 28(3):22-31. PubMed ID: 7048733 [No Abstract] [Full Text] [Related]
15. Animal models and enzyme immobilization in the development of enzyme replacement therapy: an overview. Fiddler MB Birth Defects Orig Artic Ser; 1980; 16(1):143-62. PubMed ID: 7004515 [No Abstract] [Full Text] [Related]
19. [Health economics in hepatology: who should pay? Is expensive treatment in hepatology cost effective?]. Rossol S Dtsch Med Wochenschr; 2005 Dec; 130 Suppl 5():S231-3. PubMed ID: 16435721 [No Abstract] [Full Text] [Related]